Consistent with this, treatment with Menin inhibitor (MI), e.g., SNDX-50469, SNDX-5613 (revumenib) or ziftomenib, inhibits HOXA9/MEIS1 and induces in vitro growth inhibition, differentiation, and loss of viability of AML cells expressing mtNPM1 [20–23]. This evidence concerns the gene HOXA9 and acute myeloid leukemia.